E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 diabetes |
Type 2 diabetes |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012601 |
E.1.2 | Term | Diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this trial is to determine whether 6 months Liraglutide treatment is associated with improvement in atherosclerotic phenotype through anti-inflammatory effects compared to placebo.
|
|
E.2.2 | Secondary objectives of the trial |
Possible mechanisms causing the anti-atherosclerotic effect will be explored. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Given written informed consent
2) Male or female patients >50 years with type 2 diabetes (WHO criteria)
3) HbA1c ≥ 48 mmol/mol (6.5 %)
4) eGFR ≥ 30 ml/min/1.73 m2 (estimated by CKD-epi formula)
5) Stable glucose-lowering medication for at least 4 weeks before the baseline PET/CT (excluding oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon like peptide-1 agonists and other agents, which in the investigator’s opinion could interfere with the effect of liraglutide)
6) Stable/no treatment of hypercholesterolemia 4 weeks before baseline PET/CT
7) Must be able to communicate with the investigator and understand informed consent.
|
|
E.4 | Principal exclusion criteria |
1) Type 1 diabetes mellitus
2) Chronic pancreatitis / previous acute pancreatitis
3) Known or suspected hypersensitivity to trial product(s) or related products
4) Treatment 90 days prior to screening with oral glucocorticoids, calcineurin inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon like peptide-1 agonists and other agents, which in the investigator’s opinion could interfere with the effect of liraglutide
5) Cancer or any other clinically significant disorder, except for conditions associated with type 2 diabetes history, which in the investigators opinion could interfere with the results of the trial
6) Clinical signs of diabetic gastroparesis
7) Previous bowel resection
8) Impaired liver function (transaminases > two times upper reference levels)
9) Inflammatory bowel disease
10) Weight >150 kg
11) Females of childbearing potential who are pregnant, breast-feeding, intend to become pregnant or are not using adequate contraceptive methods
12) Known or suspected abuse of alcohol or narcotics
13) Subjects with personal or family history of medullary thyroid carcinoma or a personal history of multiple endocrine neoplasia type 2
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The effect of Liraglutide on vascular inflammation, assessed by FDG-PET/CT. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At the beginning of the trial and after 26 weeks of treatment. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints includes:
1) The effect of Liraglutide treatment on endothelial dysfunction, assessed with endo-PAT and sublingual glycocalyx measurement.
2) The effect of Liraglutide treatment on coronary artery calcium score
3) The effect of Liraglutide treatment on carotid intima media thickness
4) The effect of Liraglutide treatment on circulating biomarkers of atherosclerosis
5) The effect of Liraglutide treatment on peripheral blood mononuclear cell gene expression
Exploratory endpoints:
1) Agreement between the 64Cu-DOTATATE PET/CT and the FDG PET/CT examination for evaluation of vascular inflammation.
2) Change from baseline to week 26 in vascular inflammation, assessed by 64Cu-DOTATATE.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At the beginning of the trial and after 26 weeks of treatment. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |